PT  - JOURNAL ARTICLE
AU  - Dumbrava, Ecaterina
AU  - Mestres, Joan Albanell
AU  - Ascierto, Paolo Antonio
AU  - Blay, Jean-Yves
AU  - Champiat, Stéphane
AU  - Salgado, Alfonso Cortes
AU  - Deleuze, Antoine
AU  - GilMartin, Marta
AU  - Heeke, Arielle
AU  - Italiano, Antoine
AU  - Kang, Yoon-Koo
AU  - Lee, Jeeyun
AU  - Lee, Keun-Wook
AU  - Losurdo, Agnese
AU  - Magni, Michele
AU  - Moore, Kathleen
AU  - Benzaquen, Ana Oaknin
AU  - Zabalza, Ignacio Ortego
AU  - Park, Haeseong
AU  - Rodriguez, Luis Paz-Ares
AU  - Pegram, Mark D
AU  - Ponz-Sarvise, Mariano
AU  - Rasco, Drew
AU  - Sharma, Manish
AU  - Shergill, Ardaman
AU  - Spano, Jean-Philippe
AU  - Spira, Alexander I
AU  - Vicier, Cecile
AU  - Victoria, Ivan
AU  - Weinberg, Benjamin
AU  - Tapia, Coya
AU  - Ptacek, Jason
AU  - Alonso, Michael N
AU  - Xu, Lu
AU  - Yin, Ming
AU  - Perez, Edith A
AU  - Li, Bob T
TI  - 716 Phase 2 study of the HER2-targeting TLR7/8 immune stimulating antibody conjugate (ISAC) BDC-1001 monotherapy +/- nivolumab in patients with HER2+ colorectal, endometrial, or gastroesophageal cancer
AID  - 10.1136/jitc-2023-SITC2023.0716
DP  - 2023 Nov 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - A811--A811
VI  - 11
IP  - Suppl 1
4099  - http://jitc.bmj.com/content/11/Suppl_1/A811.short
4100  - http://jitc.bmj.com/content/11/Suppl_1/A811.full
SO  - J Immunother Cancer2023 Nov 01; 11
AB  - Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.